Think Fungus: Fungal Disease Awareness Week Aug 8, 2017
Jeff Stein and others explore the antifungal public health crisis and the need for next-generation antifungal treatments at the BIO International Convention June 20, 2017
The emerging battle against fungal infections – What healthcare organizations can do to help Jan 19, 2017
Jeffrey Stein, Ph.D., President and CEO of Cidara, Elected Chairman of the Antimicrobials Working Group Jan 11, 2017
Bacteriome and Mycobiome Interactions Underscore Microbial Dysbiosis in Familial Crohn’s Disease Sep 20 2016
Antifungals in the Cloud Aug 25, 2016
Top San Diego Financings of 2015 Feb 5, 2016
Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth Jan 5, 2016
IDSA Updates Clinical Guidelines for Candidiasis: Shift to Echinocandins for Initial Treatment [Guidelines PDF; Press Release] Dec 17, 2015
When was Cidara founded?
Cidara was founded in 2012.
Who founded the company?
Cidara Therapeutics was co-founded by Kevin Forrest, Ph.D., of 5AM Ventures, Kevin Judice, Ph.D., founder and former chief executive officer of Achaogen Pharmaceuticals, and H. Shaw Warren, M.D., of Harvard University and Massachusetts General Hospital.
Where is Cidara’s corporate headquarters?
The company is headquartered in San Diego, California.
Who are the members of Cidara’s management team?
Cidara has assembled a team of senior executives with significant experience in the anti-infective market and a track record of successfully developing and commercializing many anti-infective products. You can view our management team by visiting the “Management Team” section of our website.
Who are the members of Cidara’s Board of Directors?
You can view our Board of Directors by visiting the “Board of Directors” section of our website.
On which exchange is Cidara listed and what is the ticker symbol?
Cidara is traded on The NASDAQ Global Market under the symbol “CDTX.” Cidara went public on April 15, 2015.
What are key therapeutic areas of focus for Cidara?
Cidara’s focus is on the discovery and development of new anti-infectives and immunotherapies for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Key therapeutic areas focus on invasive fungal infections, as well as efforts to leverage the immune system to treat bacterial, fungal and viral infections.
What products comprise Cidara’s initial portfolio?
Cidara’s lead product candidate is a novel echinocandin antifungal, rezafungin, intended for the treatment and prevention of life-threatening invasive fungal infections. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. Cidara’s lead Cloudbreak compound is CD201, targeting multi-drug resistant Gram-negative infections.
Where can I find more information about Cidara’s R&D programs?
You can view information about our development programs by visiting the “Drug Candidates” section of our website.
What is the market opportunity for new antifungals?
The current global market for systemic antifungals is roughly four billion dollars and there is still significant unmet need, with on-treatment mortality rates ranging from 30 to 50 percent for invasive infections. Currently, there are only three classes of antifungals approved to treat these infections and few antifungals in development. With rising resistance to existing drugs, and given their limitations of toxicity, drug interactions, or once daily IV therapy, the profile of rezafungin will be well-positioned to address patients’ unmet needs.
When did Cidara receive QIDP/Fast Track designation from the FDA for rezafungin? What does this mean?
In May 2015, the U.S. Food and Drug Administration (FDA) designated Cidara’s lead antifungal product candidate, rezafungin, as a Qualified Infectious Disease Product (QIDP) with Fast Track status. The QIDP and Fast Track designation are for the use of rezafungin in the treatment of candidemia and invasive candidiasis. The QIDP designation, provided under the Generating Antibiotic Incentives Now Act (GAIN Act), offers certain incentives for the development of new antibacterial or antifungal drugs, including eligibility for Fast Track, priority review and, if rezafungin is ultimately approved by the FDA, eligibility for an additional five years of marketing exclusivity. You can view the Cidara news announcement for more information.
Who can I contact if I am a member of the media?
For media inquiries, please email firstname.lastname@example.org.